Moffitt Presentation at ASH 2021

PLENARY SESSION

Date	Time	Title	No.	Author
Dec. 12	2-4 p.m.	Primary Analysis of ZUMA 7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma	2	Frederick L. Locke, MD

FRIDAY, DEC.10 

Time	Type	Title	Author
7-10 a.m.	Satellite Symposia	MDS 2021: From Cutting Edge Definition of Disease to More Effective Treatments	David A. Sallman, MD (speaker)
11 am - 2 pm	Satellite Symposia	Diagnosis and Treatment of MF and PV: Where Are We and Where Are We Going?	Andrew T. Kuykendall, MD (speaker)
11 am - 2 pm	Satellite Symposia	Leveraging Clinical Data to Inform Treatment Decisions for Patients with MDS: An Expert Case-Based Discussion	Rami S. Komrokji, MD (speaker)

SATURDAY, DEC. 11 

Time	Type	Title	No.	Author
10 a.m.	Oral	The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial	45	Julio C. Chavez, MD
10:15 a.m.	Oral	C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms	28	Nicole D. Vincelette, PhD
2 p.m.	Oral	Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia	217	Akriti G Jain, MD
2 - 2:45 p.m.	Educational Session	CML: Success Breeds More Success - Live Q&A		Kendra Sweet, MD (chair)
3:15 p.m.	Oral	Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)	246	David A. Sallman, MD
4 p.m.	Oral	Single Cell Deconvolution of Myeloblasts Reveals Depletion of HSCs and Expansion of Inflammatory Granulocyte-Monocyte Progenitors (GMPs) Associated with Adverse Outcomes in Chronic Myelomonocytic Leukemia (CMML)	319	Abhishek Dhawan, PhD
4:15 p.m.	Oral	Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies	302	Bijal D. Shah, MD
5:30 – 7:30 p.m.	Poster	Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Identification of Dynamic Disease Features of Progression and Need for Treatment	1523	Luis E. Aguirre, MD
5:30 – 7:30 p.m.	Poster	Outcomes of Patients with AML Treated with CPX-351 Based on the 2017 ELN Risk Stratification	1250	Akriti G Jain, MD
5:30 – 7:30 p.m.	Poster	Outcomes of Patients Treated with CPX-351 As First Line Therapy for AML Based on Their Antecedent History of Myeloid Malignancy	1251	Akriti G Jain, MD
5:30 – 7:30 p.m.	Poster	Two Distinct Clinical Courses and Outcomes in T-Cell Prolymphocytic Leukemia	1389	Ashley Rose, MD
5:30 – 7:30 p.m.	Poster	Clinical Features and Treatment Outcomes of Large Granular Lymphocytic Leukemia Coexisting with Autoimmune Diseases	1391	Ning Dong, MD
5:30 – 7:30 p.m.	Poster	Can We Lower the Platelet Threshold of ≥50x109/L for Performing a Lumbar Puncture Safely in Patients with Hematological Malignancies?	1888	Aryanna Jordan, MD
5:30 – 7:30 p.m.	Poster	Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence?	1916	Shonali Midha, MD
5:30 – 7:30 p.m.	Poster	Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes	1494	Luis E. Aguirre, MD
5:30 – 7:30 p.m.	Poster	Gender Disparities in Myelodysplastic Syndromes: Phenotype, Genotype, and Outcomes	1984	Sara Marie Tinsley-Vance, PhD
5:30 – 7:30 p.m.	Poster	A Focus on Phenotype and Genotype: Racial /Ethnic Disparities in Myelodysplastic Syndromes	1985	Sara Marie Tinsley-Vance, PhD
5:30 – 7:30 p.m.	Poster	Evaluating CD83 Expression on Organ-Specific Normal Tissues to Anticipate Potential Toxicity of Novel Human CD83-Targeted Chimeric Antigen Receptor (CAR) T Cell	1697	Tony J Kurian, MD
5:30 – 7:30 p.m.	Poster	Incidence of Pleural Effusion with Dasatinib and the Effect of Switching Therapy to Bosutinib in Patients with Chronic Phase CML	1484	Akriti G Jain, MD
5:30 – 7:30 p.m.	Poster	Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence?	1916	Shonali Midha, MD
5:30 – 7:30 p.m.	Poster	Acid Ceramidase (ASAH1) Mediates Intrinsic and Intercellular Transfer of Proteasome Inhibitor Resistance in Multiple Myeloma	1206	Ryan T Bishop, PhD
5:30 – 7:30 p.m.	Poster	Efficacy of Vecabrutinib Treatment in a Murine Model of Sclerodermatous Graft-Versus-Host-Disease	1685	Kamira Maharaj, PhD

 

SUNDAY, DEC. 12

Time	Type	Title	No.	Author
9:30 a.m.	Oral	Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)	409	Asmita Mishra, MD
10:45 a.m.	Oral	Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma	402	Nancy Gillis, PhD
4:45 p.m.	Oral	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction	530	Frederick L. Locke, MD
4:45 p.m.	Oral	Assessing the Role of Venetoclax in Combination with Hypomethylating Agents in Higher Risk Myelodysplastic Syndromes	536	Rami S. Komrokji, MD
6 - 8 p.m.	Poster	Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab	6282	David Noyes
6 - 8 p.m.	Poster	High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients	2377	Virginia Olivia Volpe, MD
6 - 8 p.m.	Poster	Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies	2504	Ning Dong, MD
6 - 8 p.m.	Poster	Outcomes By Best Response with Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia	2292	Virginia Olivia Volpe, MD
6 - 8 p.m.	Poster	Real-World Bruton Tyrosine Kinase Inhibitor Treatment Patterns, Compliance, Costs, and Hospitalizations in Patients with Mantle Cell Lymphoma in the United States	3046	Bijal D. Shah, MD
6 - 8 p.m.	Poster	Change in Patients’ Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360	3052	Anna Barata, PhD
6 - 8 p.m.	Poster	Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia	2331	Somedeb Ball, MD
6 - 8 p.m.	Poster	Concurrent Monitoring of Peripheral Blood Circulating Tumor DNA and Circulating Tumor Cells in Relapsed/Refractory Follicular Lymphoma Patients Post Axicabtagene Ciloleucel, a Single Center Experience	2397	Sameh Gaballa, MD,
6 - 8 p.m.	Poster	The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria	2600	Akriti G Jain, MD
6 - 8 p.m.	Poster	Clinico-Molecular Features and Treatment Outcomes in Primary Myelofibrosis Phenotypes with Protracted Disease Dynamics	2571	Luis E. Aguirre, MD
6 - 8 p.m.	Poster	Lymphocyte Recovery Following Autologous Hematopoietic Stem Cell Transplant in Classical Hodgkin Lymphoma	2913	Ashley Rose, MD

 

Monday, DEC. 13

Time	Type	Title	No.	Author
3 p.m.	Oral	Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1-Mutated ELN Favorable Risk AML	686	Onyee Chan, MD
5 p.m.	Oral	Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes	825	David A. Sallman, MD
6-8 p.m.	Poster	The Comparison of Kte-X19 to Current Standards of Care: A Pre-Specified Synthetic Control Study Utilizing Individual Patient Level Data from Historic Clinical Trials (SCHOLAR-3)	3844	Bijal D. Shah, MD
6 - 8 p.m.	Poster	Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	3846	Javier Pinilla Ibarz, MD
6 - 8 p.m.	Poster	Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia	3658	Yumeng Zhang, MD
6 - 8 p.m.	Poster	Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia	4138	Somedeb Ball, MD
6 - 8 p.m.	Poster	Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect® Myeloid Disease Registry	3686	Rami S. Komrokji, MD
6 - 8 p.m.	Poster	Treatment Free Remission in Patients with Chronic Phase CML: A Single Center Experience	3612	Quinto J Gesiotto, MD
6 - 8 p.m.	Poster	Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial	3748	Javier Pinilla Ibarz, MD, PhD
6 - 8 p.m.	Poster	Evaluation of Early Discharge after Intensive Induction Chemotherapy in Adults with Acute Myeloid Leukemia	4043	Amanda Al-Bahou, PharmD
6 - 8 p.m.	Poster	ALK2/ALK5 Inhibition with TP0184 Improves Hematopoiesis of Primary Low Risk MDS	3669	Erika A Eksioglu, PhD, MS
6 - 8 p.m.	Poster	Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥ 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis	3929	Brandon J. Blue, MD
6 - 8 p.m.	Poster	Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials	3898	Aleksandr Lazaryan, MD
7:15 p.m.	Oral	Rationale for Selinexor Treatment in Daratumumab-Refractory MM Patients Identified By Paired Ex Vivo Drug Sensitivity and RNA-Seq	893	Praneeth Reddy Sudalagunta, PhD